Scopus h-index:17
- Home
- Profiles
Accepting New Patients
Mount Sinai Doctors
Accepting New PatientsDouglas A Tremblay, MD
Internal Medicine, Hematology-Oncology
No Patient Experience Ratings
Ruttenberg Treatment Center
212-241-9399
- About Me
- Clinical Focus
- Education & Certifications
- Locations
- Insurance
- Publications
- Industry Relationships
About Me
Douglas Tremblay, MD is an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai. Dr. Tremblay completed fellowship and residency training at Mount Sinai where he served as both Chief Fellow and Chief Resident. His clinical and translational research focus is on hematologic malignancies, particularly acute myeloid leukemia (AML), myeloproliferative neoplasms (MPNs), and myelodysplastic/myeloproliferative overlap syndromes. Dr. Tremblay has led multi-institutional research efforts in MPNs and is actively involved in both investigator-initiated and industry sponsored early and late phase clinical trials in myeloid neoplasms.
Language
Position
Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai Morningside and Mount Sinai West
About Me
Douglas Tremblay, MD is an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai. Dr. Tremblay completed fellowship and residency training at Mount Sinai where he served as both Chief Fellow and Chief Resident. His clinical and translational research focus is on hematologic malignancies, particularly acute myeloid leukemia (AML), myeloproliferative neoplasms (MPNs), and myelodysplastic/myeloproliferative overlap syndromes. Dr. Tremblay has led multi-institutional research efforts in MPNs and is actively involved in both investigator-initiated and industry sponsored early and late phase clinical trials in myeloid neoplasms.
Language
Position
Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai Morningside and Mount Sinai West
About Me
Douglas Tremblay, MD is an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai. Dr. Tremblay completed fellowship and residency training at Mount Sinai where he served as both Chief Fellow and Chief Resident. His clinical and translational research focus is on hematologic malignancies, particularly acute myeloid leukemia (AML), myeloproliferative neoplasms (MPNs), and myelodysplastic/myeloproliferative overlap syndromes. Dr. Tremblay has led multi-institutional research efforts in MPNs and is actively involved in both investigator-initiated and industry sponsored early and late phase clinical trials in myeloid neoplasms.
Language
Position
Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai Morningside and Mount Sinai West
Clinical Focus
- Acute Myeloid Leukemia
- Anemia
- Chronic Myelocytic Leukemia
- Eosinophilia
- Essential Thrombocythemia
- Leukemia
- Myelodysplastic Syndromes
- Myelofibrosis
- Myeloproliferative Neoplasms (MPN)
Show More
- Acute Myeloid Leukemia
- Anemia
- Chronic Myelocytic Leukemia
- Eosinophilia
- Essential Thrombocythemia
- Leukemia
- Myelodysplastic Syndromes
- Myelofibrosis
- Myeloproliferative Neoplasms (MPN)
- Polycythemia Vera
- Primary Polycythemia
Education
MD, Albert Einstein College of Medicine
Residency, Internal Medicine
The Mount Sinai Hospital
Fellowship, Hematology-Oncology
Mount Sinai Hospital
Certifications
Hematology
American Board of Internal Medicine
Locations
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
- Ruttenberg Treatment Center1470 Madison Avenue, 3rd Floor, New York, NY, 10029
- 1199 SEIU
- AETNA - Commercial
- AETNA - Medicare
- Affinity Medicaid-Medicare-Essential Exchange
- AgeWell New York
- Amidacare Medicaid
- CIGNA Healthcare
- Centivo
- Elderplan
- EmblemHealth - GHI-PPO
- EmblemHealth - HIP
- EmblemHealth - HIP-Medicare
- Empire Blue Cross Blue Shield - Commercial/Exchange
- Empire Blue Cross Blue Shield - Healthplus FKA Amerigroup Medicaid
- Empire Blue Cross Blue Shield - Medicare
- Fidelis Health Care
- HealthFirst Medicaid
- HealthFirst Medicare
- Horizon NJ
- Hotel Trades
- Magnacare-Health Care
- Medicare
- Metroplus
- Multiplan PHCS
- NY Medicaid
- Oxford - Freedom & Liberty
- Partners Health Plan
- Select Health Medicaid - VNSNY
- Senior Whole Health
- United Health Care - Commercial
- United Health Care - Community Care Medicaid
- United Health Care - Empire Plan
- United Health Care - Oxford Care
- United Health Care - Top Tier
- VNSNY Choice Medicare
- VillageCareMax
- WellCare Health Plan
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Article:51
Review Article:27
Letter:16
Editorial:1
Chapter:1
Recent Artifacts
- New Treatments for Myelofibrosis
- Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Considerations and Unmet Needs
- Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19: A Phase 2 Randomized Clinical Trial
- Impact of Fluoroquinolone Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients
- Thrombocytopenia in Patients With Myelofibrosis: A Practical Management Guide
- Splanchnic vein thrombosis associated with myeloproliferative neoplasms
- The Quantification and Significance of Extramedullary Hematopoiesis Seen on Liver Biopsy Specimens
- Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database
- Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study
- Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Tremblay during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- MPN Research Foundation
- AbbVie Inc.
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
- Real CME
- Primum
- DAVA Oncology, LP
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.